Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV

The impact of imatinib dose on response rates and survival in older patients with chronic myeloid leukemia in chronic phase has not been studied well. We analyzed data from the German CML-Study IV, a randomized five-arm treatment optimization study in newly diagnosed BCR-ABL-positive chronic myeloid...

Descripción completa

Detalles Bibliográficos
Autores principales: Proetel, Ulrike, Pletsch, Nadine, Lauseker, Michael, Müller, Martin C., Hanfstein, Benjamin, Krause, Stefan W., Kalmanti, Lida, Schreiber, Annette, Heim, Dominik, Baerlocher, Gabriela M., Hofmann, Wolf-Karsten, Lange, Elisabeth, Einsele, Hermann, Wernli, Martin, Kremers, Stephan, Schlag, Rudolf, Müller, Lothar, Hänel, Mathias, Link, Hartmut, Hertenstein, Bernd, Pfirrmann, Markus, Hochhaus, Andreas, Hasford, Joerg, Hehlmann, Rüdiger, Saußele, Susanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4050299/
https://www.ncbi.nlm.nih.gov/pubmed/24658964
http://dx.doi.org/10.1007/s00277-014-2041-0

Ejemplares similares

Ejemplares similares